Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing Data

References

• Constantinidou A, Alifieris C, Trafalis DT. Targeting programmed cell death −1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy. Pharmacol Ther. 2019;194:84–18. doi:10.1016/j.pharmthera.2018.09.008.
   PubMed Web of Science ®Google Scholar
• Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res. 2018;24(6):1260–1270. doi:10.1158/1078-0432.CCR-17-2267.
   PubMed Web of Science ®Google Scholar
• Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492–1504. doi:10.1093/annonc/mdw217.
   PubMed Web of Science ®Google Scholar
• Pitt JM, Vetizou M, Daillere R, Roberti MP, Yamazaki T, Routy B. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 2016;44(6):1255–1269. doi:10.1016/j.immuni.2016.06.001.
   PubMed Web of Science ®Google Scholar
• Zhang M, Yang H, Wan L, Wang Z, Wang H, Ge C. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J Hepatol. 2020;73(5):1118–1130. doi:10.1016/j.jhep.2020.05.039.
   PubMed Web of Science ®Google Scholar
• Xiong X, Kuang H, Ansari S, Liu T, Gong J, Wang S. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol Cell. 2019;75(3):644–60 e5. doi:10.1016/j.molcel.2019.07.028.
   PubMed Web of Science ®Google Scholar
• Duhen T, Duhen R, Montler R, Moses J, Moudgil T, De Miranda NF. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9(1):2724. doi:10.1038/s41467-018-05072-0.
   PubMed Web of Science ®Google Scholar
• Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557(7706):575–579. doi:10.1038/s41586-018-0130-2.
   PubMed Web of Science ®Google Scholar
• Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019;25(8):1251–1259. doi:10.1038/s41591-019-0522-3.
   PubMed Web of Science ®Google Scholar
• Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ. CD96 is an immune checkpoint that regulates CD8(+) T-cell antitumor function. Cancer Immunol Res. 2019;7(4):559–571. doi:10.1158/2326-6066.CIR-18-0637.
   PubMed Web of Science ®Google Scholar
• Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C. T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. Sci Transl Med. 2018;10(436). doi:10.1126/scitranslmed.aan3311.
   PubMed Web of Science ®Google Scholar
• Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE. Cell surface CD74-MIF interactions drive melanoma survival in response to interferon-gamma. J Invest Dermatol. 2015;135(11):2901. doi:10.1038/jid.2015.259.
   PubMed Web of Science ®Google Scholar
• Van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell. 2018;175(7):1744–55 e15. doi:10.1016/j.cell.2018.10.028.
   PubMed Web of Science ®Google Scholar
• Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20(3):173–185. doi:10.1038/s41577-019-0224-6.
   PubMed Web of Science ®Google Scholar
• Bandala-Sanchez E, Zhang Y, Reinwald S, Dromey JA, Lee BH, Qian J. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nat Immunol. 2013;14(7):741–748. doi:10.1038/ni.2610.
   PubMed Web of Science ®Google Scholar
• Kassahn D, Nachbur U, Conus S, Micheau O, Schneider P, Simon HU. Distinct requirements for activation-induced cell surface expression of preformed Fas/CD95 ligand and cytolytic granule markers in T cells. Cell Death Differ. 2009;16(1):115–124. doi:10.1038/cdd.2008.133.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhong M, Wang C, Xu Y, Gao WQ, Zhang Y. CCL5-deficiency enhances intratumoral infiltration of CD8(+) T cells in colorectal cancer. Cell Death Dis. 2018;9(7):766. doi:10.1038/s41419-018-0796-2.
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S. Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. Cell. 2017;168(3):542. doi:10.1016/j.cell.2017.01.010.
   PubMed Web of Science ®Google Scholar
• Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171(4):934–49 e16. doi:10.1016/j.cell.2017.09.028.
   PubMed Web of Science ®Google Scholar
• Amato CM, Hintzsche JD, Wells K, Applegate A, Gorden NT, Vorwald VM. Pre-treatment mutational and transcriptomic landscape of responding metastatic melanoma patients to Anti-PD1 immunotherapy. Cancers (Basel). 2020;12(7). doi:10.3390/cancers12071943.
   Web of Science ®Google Scholar
• Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J. Distinct immune cell populations define response to Anti-PD-1 monotherapy and Anti-PD-1/Anti-CTLA-4 combined therapy. Cancer Cell. 2019;35(2):238–55 e6. doi:10.1016/j.ccell.2019.01.003.
   PubMed Web of Science ®Google Scholar
• Efremova M, Vento-Tormo M, Teichmann SA, Vento-Tormo R. CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat Protoc. 2020;15(4):1484–1506. doi:10.1038/s41596-020-0292-x.
   PubMed Web of Science ®Google Scholar
• Vento-Tormo R, Efremova M, Botting RA, Turco MY, Vento-Tormo M, Meyer KB. Single-cell reconstruction of the early maternal-fetal interface in humans. Nature. 2018;563(7731):347–353. doi:10.1038/s41586-018-0698-6.
   PubMed Web of Science ®Google Scholar
• Xu Q, Long Q, Zhu D, Fu D, Zhang B, Han L. Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression. Aging Cell. 2019;18(6):e13027. doi:10.1111/acel.13027.
   PubMed Web of Science ®Google Scholar
• Tinoco R, Carrette F, Barraza ML, Otero DC, Magana J, Bosenberg MW. PSGL-1 is an immune checkpoint regulator that promotes T Cell exhaustion. Immunity. 2016;44(6):1470. doi:10.1016/j.immuni.2016.05.011.
   PubMed Web of Science ®Google Scholar
• Tinoco R, Otero DC, Takahashi AA, Lm B. PSGL-1: a new player in the immune checkpoint landscape. Trends Immunol. 2017;38(5):323–335. doi:10.1016/j.it.2017.02.002.
   PubMed Web of Science ®Google Scholar
• Chou FC, Chen HY, Kuo CC, Sytwu HK. Role of galectins in tumors and in Clinical immunotherapy. Int J Mol Sci. 2018;19(2). doi:10.3390/ijms19020430.
   Web of Science ®Google Scholar
• Jmj VDB, Smits E, Berneman ZN, Hutten TJA, De Reu H, Vfi VT. Monocyte-derived dendritic cells with silenced PD-1 ligands and transpresenting interleukin-15 stimulate strong tumor-reactive T-cell expansion. Cancer Immunol Res. 2017;5(8):710–715. doi:10.1158/2326-6066.CIR-16-0336.
   PubMed Web of Science ®Google Scholar
• Luo C, Balsa E, Perry EA, Liang J, Tavares CD, Vazquez F. H3K27me3-mediated PGC1alpha gene silencing promotes melanoma invasion through WNT5A and YAP. J Clin Invest. 2020;130(2):853–862. doi:10.1172/JCI130038.
   PubMed Web of Science ®Google Scholar
• Zhao F, Xiao C, Evans KS, Theivanthiran T, DeVito N, Holtzhausen A. Paracrine Wnt5a-beta-catenin signaling triggers a metabolic program that drives dendritic cell tolerization. Immunity. 2018;48(1):147–60 e7. doi:10.1016/j.immuni.2017.12.004.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhu H, Tiruthani K, Shen L, Chen F, Gao K. Nanoparticle-mediated trapping of Wnt family member 5A in tumor microenvironments enhances immunotherapy for B-Raf Proto-Oncogene mutant melanoma. ACS Nano. 2018;12(2):1250–1261. doi:10.1021/acsnano.7b07384.
   PubMed Web of Science ®Google Scholar
• Cr F, Ra A, Mousdell S, Pt R-L, Ireland L, Santos A. Blockade of MIF-CD74 signalling on macrophages and dendritic cells restores the antitumour immune response against metastatic melanoma. Front Immunol. 2018;9:1132. doi:10.3389/fimmu.2018.01132.
   PubMed Web of Science ®Google Scholar
• Yin Y, Xu X, Tang J, Zhang W, Zhangyuan G, Ji J. CD97 promotes tumor aggressiveness through the traditional G protein-coupled receptor-mediated signaling in hepatocellular carcinoma. Hepatology. 2018;68(5):1865–1878. doi:10.1002/hep.30068.
   PubMed Web of Science ®Google Scholar
• Geller A, Yan J. The role of membrane bound complement regulatory proteins in tumor development and cancer immunotherapy. Front Immunol. 2019;10:1074. doi:10.3389/fimmu.2019.01074.
   PubMed Web of Science ®Google Scholar
• Daniel SK, Seo YD, Pillarisetty VG. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies. Semin Cancer Biol. 2019. doi:10.1016/j.semcancer.2019.12.007.
   PubMed Web of Science ®Google Scholar
• Catusse J, Leick M, Groch M, Clark DJ, Buchner MV, Zirlik K. Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia. Mol Cancer. 2010;9(1):297. doi:10.1186/1476-4598-9-297.
   PubMed Web of Science ®Google Scholar
• Leick M, Catusse J, Follo M, Nibbs RJ, Hartmann TN, Veelken H. CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B. Immunology. 2010;129(4):536–546. doi:10.1111/j.1365-2567.2009.03209.x.
   PubMed Web of Science ®Google Scholar
• Milicevic NM, Miljkovic MD, Milicevic Z, Labudovic-Borovic M, Wang X, Laan M. Role of CCL19/21 and its possible signaling through CXCR3 in development of metallophilic macrophages in the mouse thymus. Histochem Cell Biol. 2011;135(6):593–601. doi:10.1007/s00418-011-0818-y.
   PubMed Web of Science ®Google Scholar
• Robles O, Jackson JJ, Marshall L, Talay O, Chian D, Cutler G. Novel Piperidinyl-Azetidines as potent and selective CCR4 antagonists elicit antitumor response as single agent and in combination with checkpoint inhibitors. J Med Chem. 2020;15. doi:10.1021/acs.jmedchem.0c00988.
   PubMed Web of Science ®Google Scholar
• Williford JM, Ishihara J, Ishihara A, Mansurov A, Hosseinchi P, Marchell TM. Recruitment of CD103(+) dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy. Sci Adv. 2019;5(12):eaay1357. doi:10.1126/sciadv.aay1357.
   PubMed Web of Science ®Google Scholar
• Bernardini G, Hedrick J, Sozzani S, Luini W, Spinetti G, Weiss M. Identification of the CC chemokines TARC and macrophage inflammatory protein-1 beta as novel functional ligands for the CCR8 receptor. Eur J Immunol. 1998;28(2):582–588. doi:10.1002/(SICI)1521-4141(199802)28:02<582::AID-IMMU582>3.0.CO;2-A.
   PubMed Web of Science ®Google Scholar
• Tsukita Y, Fujino N, Miyauchi E, Saito R, Fujishima F, Itakura K. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas. Mol Cancer. 2019;18(1):24. doi:10.1186/s12943-019-0953-y.
   PubMed Web of Science ®Google Scholar
• Holtzhausen A, Harris W, Ubil E, Hunter DM, Zhao J, Zhang Y. TAM family receptor kinase inhibition reverses MDSC-mediated suppression and augments Anti-PD-1 therapy in Melanoma. Cancer Immunol Res. 2019;7(10):1672–1686. doi:10.1158/2326-6066.CIR-19-0008.
   PubMed Web of Science ®Google Scholar
• Sadahiro H, Kang KD, Gibson JT, Minata M, Yu H, Shi J. Activation of the receptor Tyrosine Kinase AXL regulates the immune microenvironment in glioblastoma. Cancer Res. 2018;78(11):3002–3013. doi:10.1158/0008-5472.CAN-17-2433.
   PubMed Web of Science ®Google Scholar
• Fromm G, De Silva S, Johannes K, Patel A, Hornblower JC, Schreiber TH. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy. J Immunother Cancer. 2018;6(1):149. doi:10.1186/s40425-018-0454-3.
   PubMed Web of Science ®Google Scholar
• Ahn SH, Choi JY, Kim SD, Park SJ, Kim H. Accelerated elimination of human cancer cells by a CD40 agonist antibody combined with a PD-1 antagonist in CD4-depleted mice. Oncol Lett. 2019;18(6):5889–5896. doi:10.3892/ol.2019.10991.
   PubMed Web of Science ®Google Scholar
• Ma HS, Poudel B, Torres ER, Sidhom JW, Robinson TM, Christmas B. A CD40 Agonist and PD-1 Antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity. Cancer Immunol Res. 2019;7(3):428–442. doi:10.1158/2326-6066.CIR-18-0061.
   PubMed Web of Science ®Google Scholar
• Terabe M, Robertson FC, Clark K, De Ravin E, Bloom A, Venzon DJ. Blockade of only TGF-beta 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. Oncoimmunology. 2017;6(5):e1308616. doi:10.1080/2162402X.2017.1308616.
   PubMed Web of Science ®Google Scholar
• Leclerc M, Voilin E, Gros G, Corgnac S, De Montpreville V, Validire P. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. Nat Commun. 2019;10(1):3345. doi:10.1038/s41467-019-11280-z.
   PubMed Web of Science ®Google Scholar
• Li H, Van Der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, Acj VA. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell. 2019;176(4):775–89 e18. doi:10.1016/j.cell.2018.11.043.
   PubMed Web of Science ®Google Scholar
• Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276(1):97–111. doi:10.1111/imr.12520.
   PubMed Web of Science ®Google Scholar
• Vandenbark AA, Meza-Romero R, Benedek G, Andrew S, Huan J, Chou YK. A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance. J Autoimmun. 2013;40:96–110. doi:10.1016/j.jaut.2012.08.004.
   PubMed Web of Science ®Google Scholar
• Kuttruff S, Koch S, Kelp A, Pawelec G, Rammensee HG, Steinle A. NKp80 defines and stimulates a reactive subset of CD8 T cells. Blood. 2009;113(2):358–369. doi:10.1182/blood-2008-03-145615.
   PubMed Web of Science ®Google Scholar
• Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA. Cooperation between constitutive and inducible chemokines enables T Cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35(6):885–900 e10. doi:10.1016/j.ccell.2019.05.004.
   PubMed Web of Science ®Google Scholar
• Beere HM. Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest. 2005;115(10):2633–2639. doi:10.1172/JCI26471.
   PubMed Web of Science ®Google Scholar
• Fukushima T, Zapata JM, Singha NC, Thomas M, Kress CL, Krajewska M. Critical function for SIP, a ubiquitin E3 ligase component of the beta-catenin degradation pathway, for thymocyte development and G1 checkpoint. Immunity. 2006;24(1):29–39. doi:10.1016/j.immuni.2005.12.002.
   PubMed Web of Science ®Google Scholar
• Wakim LM, Gupta N, Mintern JD, Villadangos JA. Enhanced survival of lung tissue-resident memory CD8(+) T cells during infection with influenza virus due to selective expression of IFITM3. Nat Immunol. 2013;14(3):238–245. doi:10.1038/ni.2525.
   PubMed Web of Science ®Google Scholar
• Ss C, Bc P, Ak S, Ld R, Dj S, Us K. Tumor-specific effector CD8+ T Cells that can establish immunological memory in humans after adoptive transfer are marked by expression of IL7 receptor and c-myc. Cancer Res. 2015;75(16):3216–3226. doi:10.1158/0008-5472.CAN-15-0584.
   PubMed Web of Science ®Google Scholar
• Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99–115. doi:10.1038/s41573-018-0004-1.
   PubMed Web of Science ®Google Scholar
• Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A. 2010;107(46):20009–20014. doi:10.1073/pnas.1013805107.
   PubMed Web of Science ®Google Scholar
• Augsten M, Sjoberg E, Frings O, Vorrink SU, Frijhoff J, Olsson E. Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties. Cancer Res. 2014;74(11):2999–3010. doi:10.1158/0008-5472.CAN-13-2740.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Zhang X, Zhang L, Li W, Wu H, Yuan X. The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression. Cell Death Dis. 2014;5(6):e1295. doi:10.1038/cddis.2014.263.
   PubMed Web of Science ®Google Scholar
• Grum-Schwensen B, Klingelhofer J, Berg CH, El-Naaman C, Grigorian M, Lukanidin E. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res. 2005;65(9):3772–3780. doi:10.1158/0008-5472.CAN-04-4510.
   PubMed Web of Science ®Google Scholar
• Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016;532(7598):250–254. doi:10.1038/nature17392.
   PubMed Web of Science ®Google Scholar
• Endo M, Nishita M, Fujii M, Minami Y. Insight into the role of Wnt5a-induced signaling in normal and cancer cells. Int Rev Cell Mol Biol. 2015;314:117–148.
   PubMed Web of Science ®Google Scholar
• Unterleuthner D, Neuhold P, Schwarz K, Janker L, Neuditschko B, Nivarthi H. Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer. Angiogenesis. 2020;23(2):159–177. doi:10.1007/s10456-019-09688-8.
   PubMed Web of Science ®Google Scholar
• Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15(12):786–801. doi:10.1038/nrm3904.
   PubMed Web of Science ®Google Scholar